EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSOCUG00000015434
Gene Symbol: MAP3K5
2 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSOCUG00000006056
Gene Symbol: MAP3K8
2 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSOCUG00000003204
Gene Symbol: MAP3K9
2 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSOCUG00000001429
Gene Symbol: MAOA
2 Cross references
147 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSOCUG00000001436
Gene Symbol: MAOB
2 Cross references
329 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSOCUG00000014737
Gene Symbol: MLNR
3 Cross references
165 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSOCUG00000006526
Gene Symbol: MPO
2 Cross references
181 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSOCUG00000027588
Gene Symbol: NPR1
3 Cross references
184 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSOCUG00000006453
Gene Symbol: NPR2
2 Cross references
259 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSOCUG00000010507
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSOCUG00000016275
Gene Symbol: NPY2R
2 Cross references
246 Possible Orthologues:

Neuropeptide Y Receptor Y4

Ensembl ID : ENSOCUG00000014188
Gene Symbol: NPY4R
4 Cross references
116 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).